These results indicate that although the two compounds are structurally similar, differing by only one carbon in the middle ring, there are major differences in their metabolic activation, induding metabolism, DNA binding, mutation, and carcinogenesis. The biological differences for DBC and DBA are reflected in target-organ-specific proximate and mutagenic metabolites, DNA adduct patterns, and the resulting mutational spectra.
Seven lectures were presented at the symposium. The first presentation dealt with sources of PAHs and those that were most commonly found on the National Priority List (NPL) (1) . The PAHs are major contaminants of oily and MGP sites. A study was undertaken to investigate the in vivo carcinogenicity and in vitro genotoxicity of crude MGP-derived PAHs, B[a]P, and a reconstituted mixture of MGP-PAH hydrocarbons. Carcinogenicity studies in juvenile male B6C3F1 mice demonstrated that the hepatocarcinogenicity of MGP residues is primarily due to compounds other than the hydrocarbons. This was also confirmed in mutagenicity and fractionation assays, which suggest that alkyl PAHs may be important components of these mixtures.
The risk assessments of PAH at the EPA are carried out according to the Guidelines for the Health Risk Assessment of Chemical Mixtures (2) Appropriate physiologically based pharmacokinetic models should be applied to arrive at target doses. It should be possible to extend the observed range of the B[a]P dose response using nontumor data such as specific DNA adducts or mutation frequencies.
